OGN in “The Patent Cliff Sparks a Biotech Land Grab”
Organon & Co.
A mature product portfolio, looming exclusivity losses and significant leverage constrain Organon's ability to buy enough growth to offset erosion.
OGN impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to OGN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading OGN impact map…
Price history, marked with story events
Feb 25, 2025 – May 28, 2025 · 65 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BEAR side — A mature product portfolio, looming exclusivity losses and significant leverage constrain Organon's ability to buy enough growth to offset erosion.
Read the full The Patent Cliff Sparks a Biotech Land Grab storyBull side
1 story- America Imports the World's Drug Prices
OGN in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Organon's biosimilar portfolio and established-brands infrastructure position it to supply lower-cost therapies as substitution pressure rises.
Bear side
1 story- Viewing
OGN in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
A mature product portfolio, looming exclusivity losses and significant leverage constrain Organon's ability to buy enough growth to offset erosion.